PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30867376-9	2019	Rivaroxaban treatment decreased cardiac PAR2 levels and pro-inflammatory genes.	Rivaroxaban	0-11	pulmonary adenoma resistance 2	Mus musculus	40-44	
33693223-8	2020	Rivaroxaban also downregulated the mRNA expression levels of tumor necrosis factor-alpha, transforming growth factor-beta, PAR-1 and PAR-2 in the infarcted area, and both A-type and B-type natriuretic peptides in the non-infarcted area compared with the vehicle.	Rivaroxaban	0-11	pulmonary adenoma resistance 2	Mus musculus	133-138	
30867376-12	2019	CONCLUSIONS: Rivaroxaban treatment just after MI in Hypo E mice prevented the progression of ICM by attenuating cardiac remodeling, partially through the suppression of the PAR2-mediated inflammatory pathway.	Rivaroxaban	13-24	pulmonary adenoma resistance 2	Mus musculus	173-177	
30957622-9	2019	The renal expression of PAR -2 was increased in the Ren-TG, but was inhibited with rivaroxaban treatment.	Rivaroxaban	83-94	pulmonary adenoma resistance 2	Mus musculus	24-30	
30957622-12	2019	Conclusions These findings indicate that rivaroxaban exerts protective effects against angiotensin II-induced renal damage, partly through inhibition of the PAR -2 signaling-mediated inflammatory response.	Rivaroxaban	41-52	pulmonary adenoma resistance 2	Mus musculus	157-163	
28993090-12	2018	In cardiac fibroblasts, persistent intermittent stretch upregulated PAR-2, which was suppressed by RVX pre-incubation.	Rivaroxaban	99-102	pulmonary adenoma resistance 2	Mus musculus	68-73	
35001892-0	2022	Protective Effect of Rivaroxaban Against Amyloid Pathology and Neuroinflammation Through Inhibiting PAR-1 and PAR-2 in Alzheimer"s Disease Mice.	Rivaroxaban	21-32	pulmonary adenoma resistance 2	Mus musculus	110-115	
35001892-6	2022	RESULTS: Rivaroxaban treatment attenuated neuroinflammation, blood-brain barrier dysfunction, memory deficits, and amyloid-beta deposition through PAR-1/PAR-2 inhibition in the AD + CAA mice model compared with warfarin and no-treatment groups.	Rivaroxaban	9-20	pulmonary adenoma resistance 2	Mus musculus	153-158